Epileptic Hippocampus in Alzheimer's Disease

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

June 1, 2029

Study Completion Date

June 1, 2029

Conditions
Alzheimer DiseaseMild Cognitive Impairment
Interventions
DRUG

Brivaracetam

"* Intravenous administration: 25 mg or 50 mg will be administered depending on its effects on epileptic activity during a hospital stay where simultaneous EEG and depth electrode recordings will be measuring epileptic activity.~* Oral administration: Subjects will take 25mg or 50mg twice a day for 12 months. The dosage will depend on its effects on epileptic activity. Brivaracetam levels will be measured on months 3, 6 and 12."

Trial Locations (1)

90095-1769

Mary S. Easton Center for Alzheimer's Research and Care, Los Angeles

All Listed Sponsors
lead

University of California, Los Angeles

OTHER

NCT05899764 - Epileptic Hippocampus in Alzheimer's Disease | Biotech Hunter | Biotech Hunter